FIELD: medicine, pharmacy. SUBSTANCE: invention relates to using compound taken among D-β-hydroxybutyric acid and/or its metabolic precursor as an active component of medicinal agent or foodstuff used for treatment of diabetes mellitus, reversion, delaying or prevention of effects of neurodegenerative disorders and epilepsy, to new compounds and method for their synthesis. EFFECT: enhanced effectiveness of treatment. 21 cl, 2 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC COMPOSITIONS (U) | 1999 |
|
RU2242227C2 |
| PREVENTION AND TREATMENT OF MIGRAINE | 2017 |
|
RU2753057C2 |
| PROTECTIVE COMPOSITIONS FOR ISCHEMIA/REPERFUSION AND METHODS FOR USING THEM | 2008 |
|
RU2459624C2 |
| KETOGENIC COMPOSITION | 2021 |
|
RU2769242C1 |
| 2',3'-DIACETYLURIDINE SUBSTITUTED WITH ACETOACETYL IN 5' POSITION | 2021 |
|
RU2839363C1 |
| COMPOSITIONS AND METHODS FOR ELEVATING AND SUSTAINING KETOSIS | 2014 |
|
RU2659386C2 |
| CONCENTRATION MEASURING REAGENT AND TEST STRIPS BASED THEREON | 1999 |
|
RU2225005C2 |
| METHOD OF PRODUCING MICROBIAL COPOLYMERS FORMED BY MONOMERS OF 3-HYDROXYBUTYRIC ACID AND 4-HYDROXYBUTYRIC ACID ACIDS | 2015 |
|
RU2582255C1 |
| DIAGNOSTICS BASED UPON TETRAZOLIUM COMPOUNDS | 1999 |
|
RU2225004C2 |
| METHOD OF EARLY DIAGNOSIS OF SUBCLINICAL KETOSE IN COWS | 1992 |
|
RU2032909C1 |
